JB Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threating ("orphan") inflammatory-fibrotic diseases with clear unmet needs.  Our lead product Resunab™ is a first- in-class oral anti-inflammatory drug scheduled to enter Phase 2 studies in 2014 for the treatment of Cystic Fibrosis and Scleroderma.